Standard BioTools Inc. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Standard BioTools Inc. (LAB) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals of $12.65 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals · last filed 2026-03-16
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $12.65M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $14.67M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $3.15M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $3.94M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals as first filed |
|---|---|---|
| 2025-12-31 | $12.65M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $14.67M 10-K · filed 2026-03-16 | |
| 2023-12-31 | $3.15M 10-K · filed 2025-03-11 | |
| 2022-12-31 | $3.94M 10-K · filed 2024-03-01 | |
| 2021-12-31 | $3.47M 10-K · filed 2023-03-14 | |
| 2020-12-31 | $5.24M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $3.57M 10-K · filed 2021-02-25 | $3.60M 10-K · filed 2020-02-27 |
| 2018-12-31 | $7.17M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $3.93M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $4.28M 10-K · filed 2018-03-08 | |
| 2015-12-31 | $2.92M 10-K · filed 2017-03-03 | |
| 2014-12-31 | $4.13M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $2.47M 10-K · filed 2015-02-26 | |
| 2012-12-31 | $1.67M 10-K · filed 2014-03-12 | |
| 2011-12-31 | $1.70M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |